Vincent J. Sartori

Vincent J. Sartori

Auto-generated profile, based on publicly available information

Vincent J. Sartori

Van Andel Institute Graduate School, Grand Rapids, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2025 in Nature Metabolism
Verified
Journal Article
Open access
PDF file
FKFaith C. Kaluba
Faith C. Kaluba
TRThomas J. Rogers
Thomas J. Rogers
YJYu-Jin Jeong
Yu-Jin Jeong
RHRachel ‘rAe’ J. House
Rachel ‘rAe’ J. House
AWAlthea Waldhart
Althea Waldhart
ELEvan C. Lien
Evan C. Lien
Cancer cells are exposed to diverse metabolites in the tumour microenvironment that are used to support the synthesis of nucleotides, amino acids and lipids needed for rapid cell proliferation. In some tumours, ketone bodies such as β-hydroxybutyrate (β-OHB), which are elevated in circulation under fasting conditions or low glycemic diets, can serve as an alternative fuel that is metabolized in the mitochondria to provide acetyl-CoA for the tricarboxylic acid (TCA) cycle. Here we identify a non-canonical route for β-OHB metabolism that bypasses the TCA cycle to generate cytosolic acetyl-CoA. We show that in cancer cells that can metabolize ketones, β-OHB-derived acetoacetate in the mitochondria can be shunted into the cytosol, where acetoacetyl-CoA synthetase (AACS) and thiolase convert it into cytosolic acetyl-CoA. This alternative metabolic routing allows β-OHB to avoid oxidation in the mitochondria and to be used as a major source of cytosolic acetyl-CoA, even when other key cytosolic acetyl-CoA precursors such as glucose are available in excess. Finally, we demonstrate that ketone body metabolism, including this alternative AACS-dependent route, can support the growth of mouse Kras G12D ; Trp53 −/− pancreatic tumours grown orthotopically in the pancreas of male mice, as well as the growth of mouse B16 melanoma tumours in male mice fed a calorie-restricted diet. Together, these data reveal how cancer cells use β-OHB as a major source of cytosolic acetyl-CoA to support cell proliferation and tumour growth.

17 May 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
NBNathaniel J Buteyn
Nathaniel J Buteyn
SLSamantha J LaMantia
Samantha J LaMantia
CBConnor G Burke
Connor G Burke
VSVincent J Sartori
Vincent J Sartori
EDEve Deering-Gardner
Eve Deering-Gardner
TTTimothy J Triche
Timothy J Triche
The past 25 years of clinical trials have produced few improvements in pediatric AML (pAML) outcomes. This is acutely evident in patients with t(16;21)(p11;q22), yielding FUS::ERG . Patients with FUS::ERG -positive AML relapse quickly and do not respond to transplantation. Major histocompatibility complex (MHC) class I & II receptors and costimulatory molecules are absent at diagnosis in FUS::ERG- positive AML, mirroring the phenotype and outcomes of post-transplant relapse. We show that this is driven by overexpression of EZH2, in vitro and in multiple clinical cohorts. While FUS::ERG AML is the most extreme example, this phenotype is shared by lethal CBFA2T3::GLIS2- driven AML, and patients with RUNX1::RUNX1T1 have significantly worse outcomes when EZH2 overexpression co-occurs. The FDA-approved EZH2 inhibitor tazemetostat reverses this phenotype, re-establishes MHC presentation, and elicits immune effector cell-mediated elimination. EZH2 inhibitors may provide the first targeted therapeutic frontline option for AML patients with FUS::ERG , with the potential for broader frontline immunostimulatory benefits. STATEMENT OF SIGNIFICANCE: Here we show an immune-evasive phenotype, present at diagnosis and characterized by elevated EZH2 levels and loss of MHC class I and II, defines a high-risk subtype of acute leukemia. Treatment with the EZH2 inhibitor tazemetostat and IFN-γ reverses this phenotype and results in immune cell engagement and blast elimination.

26 September 2026 in Blood Neoplasia
Verified
Journal Article
Open access
NBNathaniel J Buteyn
Nathaniel J Buteyn
SLSamantha J LaMantia
Samantha J LaMantia
CBConnor G Burke
Connor G Burke
VSVincent J Sartori
Vincent J Sartori
YHYizhou Peter Huang
Yizhou Peter Huang
TTTimothy J Triche
Timothy J Triche